Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ) Latest Company News

Oct 29, 2026, 07:55 UTC
Changshan Pharmaceutical reported revenue of 736 million yuan, up 8.10% year over year, and a net loss of 37.8944 million yuan for the first three quarters of 2026.
Source:
- finance.sina.cn
Oct 29, 2026, 07:55 UTC
Changshan Pharmaceutical reported third-quarter 2026 revenue of 261 million yuan, up 37.41% year over year, and a net loss of 21.1326 million yuan.
Source:
- finance.sina.cn
Oct 16, 2026, 07:55 UTC
Changshan Pharmaceutical said its enoxaparin sodium injection received a drug registration certificate from Mongolia’s drug regulator.
Source:
- finance.sina.cn
Sep 16, 2026, 11:57 UTC
Changshan Pharmaceuticals announced on September 16 that it received investors' online questions in a research session, with Chairman Gao Xiaodong, Board Secretary Liu Zhongying, and CFO Yue Xiaohua receiving them.
Source:
- wap.eastmoney.com
Sep 15, 2026, 08:46 UTC
Changshan Pharmaceuticals announced that its heparin sodium injection received a drug registration certificate from Moldova's drug regulatory authority.
Source:
- finance.sina.cn
Sep 7, 2026, 07:51 UTC
Gao Xiaodong resigned as general manager of Changshan Pharmaceutical, with Chang Yanlu acting as interim general manager.
Source:
- finance.sina.cn
Aug 3, 2026, 07:47 UTC
Changshan Pharmaceutical announced that its dalteparin sodium injection was provisionally selected in the 12th batch of national centralized drug procurement, with the procurement cycle lasting until December 31, 2029.
Source:
- finance.sina.cn

300255.SZ

Changshan Pharmaceutical reported revenue of 736 million yuan, up 8.10% year over year, and a net loss of 37.8944 million yuan for the first three quarters of 2026.

Changshan Pharmaceutical reported third-quarter 2026 revenue of 261 million yuan, up 37.41% year over year, and a net loss of 21.1326 million yuan.

Changshan Pharmaceutical said its enoxaparin sodium injection received a drug registration certificate from Mongolia’s drug regulator.

Changshan Pharmaceuticals announced on September 16 that it received investors' online questions in a research session, with Chairman Gao Xiaodong, Board Secretary Liu Zhongying, and CFO Yue Xiaohua receiving them.

Changshan Pharmaceuticals announced that its heparin sodium injection received a drug registration certificate from Moldova's drug regulatory authority.

Gao Xiaodong resigned as general manager of Changshan Pharmaceutical, with Chang Yanlu acting as interim general manager.

Changshan Pharmaceutical announced that its dalteparin sodium injection was provisionally selected in the 12th batch of national centralized drug procurement, with the procurement cycle lasting until December 31, 2029.